India Export Medicines To Which Countries? Verified Partners & Suppliers In Q1/2026

Key Takeaways

• India export medicines to which countries? According to yTrade Q1/2026 data: United States (US$1.3 billion), Germany (US$1.1 billion), and Mexico (US$305.5 million) lead Indian pharmaceutical exports under HS 30
• India's pharmaceutical exports crossed US$31 billion in FY26 despite an 11.54% contraction in the US market, with geographic rebalancing driving growth across Africa, Latin America, and Southeast Asia
• Generic medicaments in measured retail doses (HS 300490) dominate across all top five destination markets, reinforcing India's position as the world's largest supplier of generic drugs, accounting for 20% of global generic exports by volume, as reported by the IBEF.

All data in this article is sourced from yTrade, the most affordable trade data platform on the market with access to 5 billion+ verified trade records, 480 million+ importers and exporters, and 1 million+ data points processed daily across 200+ countries.

India Export Medicines To Which Countries? Top Indian Medicine Exporting Partners

India exports medicines primarily to the United States (US$1.3 billion, 17.56%), Germany (US$1.1 billion, 14.20%), and Mexico (US$305.5 million, 4.11%) in Q1/2026. Under HS 30, India shipped pharmaceutical products to over 200 countries in FY26, with generic drug formulations and biologicals constituting the bulk of trade.

According to IBEF, India ranks third globally by pharmaceutical export volume and is the world's largest supplier of generic medicines, with one in five generic drugs sold worldwide originating from Indian manufacturing facilities.

Rank	Country	Value (US$)	Share %	Shipments	Economic Importance
1	United States	$1.3B	17.56%	28,879	India's largest market; primary driver of commercial generic manufacturing revenue.
2	Germany	$1.1B	14.20%	3,658	Premium European hub sourcing high-quality formulations and active pharmaceutical ingredients.
3	Mexico	$305.5M	4.11%	4,216	Core Latin American gateway for affordable Indian generic retail distribution network.
4	Kenya	$261.8M	3.52%	10,067	Vital East African consumer highly dependent on Indian supply for public healthcare.
5	Philippines	$225.6M	3.03%	9,363	Key Southeast Asian market importing cost-effective medical treatments and therapeutics.
6	United Kingdom	$158.1M	2.13%	8,012	Major Western market utilizing regulated Indian generics to reduce public health costs.
7	Uganda	$150.0M	2.02%	5,597	Strategic African partner sourcing affordable Indian medicines for national immunization and treatment.
8	France	$144.8M	1.95%	6,952	Strict regulatory destination sourcing specialized generic variants and chemical compounds.
9	Sri Lanka	$143.5M	1.93%	5,833	Close neighbor relying on immediate cross-border shipments to stabilize pharmacy deficits.
10	Uzbekistan	$130.3M	1.75%	2,142	Central Asian trade anchor securing essential generic drugs for regional distribution.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

India exports medicines to which countries reveal a three-tier market structure.

The US and Germany together absorb over 31% of total value as high-regulated, high-value markets.

• Mid-tier destinations like Mexico, Kenya, Philippines, UK, France, represent a mix of emerging generics demand and established procurement frameworks.
• Smaller markets, Uganda, Sri Lanka, Uzbekistan, reflect India's role as the affordable pharmacy for developing economies.

According to India Med Today, Indian pharma exports crossed US$31 billion in FY26 despite headwinds from the US market, where exports contracted 11.54% year-on-year. Growth was driven by geographic diversification into Africa, Latin America, and Central Asia.

Unlock deeper trade data on each pharmaceutical category across India's 200+ export markets. yTrade trade data platform lets you filter by HS code, destination, supplier, and time period, verified by 5 billion+ customs records.

Top 1 Indian Medicine Export Partner: United States — US$1.3 Billion

The United States is the largest destination for India exporting medicines to which countries are US$1.3 billion (17.56%) in Q1/2026. Generic medications in measured retail doses (HS 300490) dominate bilateral trade at 86.85%, reflecting India's role as the primary source of affordable generic drugs for the American healthcare system.

Rank	6-Digit HS Code	Value (US$)	Share %	Shipments	Product Description
1	300490	$1.1B	86.85%	23,392	Generic or branded medicaments in measured retail doses for general clinical treatments.
2	300420	$54.8M	4.20%	925	Antibiotic medicaments put up in measured dosage forms for direct consumer use.
3	300410	$33.5M	2.56%	451	Medicaments containing penicillins or structural derivatives prepared in therapeutic retail doses.
4	300190	15.6M	1.19%	312	Prepared human or animal substances utilized for specialized prophylactic or therapeutic processing.
5	300439	12.9M	0.99%	197	Specialized hormone-based medicaments put up in measured retail doses for patient care.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

The US remains India's single largest pharmaceutical export market despite contracting 11.54% in FY26. As reported by the Times of India, US pharma exports were valued at US$8.95 billion in FY25 with 14.29% growth, but tariff uncertainty and FDA regulatory tightening slowed momentum through FY26.

Highlights of India-US pharmaceutical trade:

• Generic drug dependency — The US is India's largest single pharmaceutical market, with exports valued at US$8.95 billion in FY25 — 14.29% growth year-on-year
• FY26 contraction — The 11.54% decline was driven by pre-tariff front-loading in FY25, when exporters rushed to ship before proposed reciprocal tariffs took effect, followed by demand normalization
• Regulated market dominance — According to Times of India, more than 60% of India's pharma exports head to highly regulated markets, with the US alone accounting for around 34% of total pharmaceutical exports

Top 2 Indian Medicine Export Partner: Germany — US$1.1 Billion

Germany ranks second among India export medicines to which countries at US$1.1 billion (14.20%) in Q1/2026.

The trade is even more concentrated than in the US, where generic medicaments (HS 300490) command 98.39% of bilateral value, showing Germany's aggressive generic substitution policies and its role as a re-distribution hub for Indian pharmaceuticals across Europe.

Noticable events between India-Germany pharmaceutical trade:

• EU gateway — German pharmaceutical wholesalers distribute Indian generics across the EU single market, amplifying the bilateral trade's downstream reach
• API sourcing — German pharmaceutical companies also source Active Pharmaceutical Ingredients (APIs) from India, with a separate trade flow under HS 29 not captured in HS 30 data
• Quality standards moat — German regulatory standards (BfArM) serve as a de facto quality seal for Indian manufacturers selling across Europe

Rank	6-Digit HS Code	Value (US$)	Share %	Shipments	Product Description
1	300490	$1.0B	98.39%	2,675	Generic or branded medicaments in measured retail doses for general clinical treatments.
2	300390	$8.8M	0.84%	48	Bulk mixed medicaments intended for therapeutic use, not divided into retail doses.
3	300410	$2.3M	0.22%	51	Medicaments containing penicillins or structural derivatives prepared in therapeutic retail doses.
4	300439	$1.5M	0.14%	8	Specialized hormone-based medicaments put up in measured retail doses for patient care.
5	300590	$1.2M	0.11%	554	Medical wadding, gauze, and bandages coated or impregnated with active pharmaceutical materials.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

yTrade allows tracking trade activity across competitors, regions, and product categories, which identified market share shifts before they impact the trade strategy. Monitor trade movements between India and Germany across all pharmaceutical HS codes on yTrade's market and competitor monitoring tools.

Top 3 Indian Medicine Export Partner: Mexico — US$305.5 Million

Mexico is India's third-largest pharmaceutical export destination at US$305.5 million (4.11%) in Q1/2026.

The main medicines exported from India to Mexica are generic medicaments (HS 300490) lead at 56.81%, preventative human vaccines (HS 300241) hold a notable 20.45% share, a result of Mexico's large-scale public immunization programs.

Rank	6-Digit HS Code	Value (US$)	Share %	Shipments	Product Description
1	300490	$173.5M	56.81%	3,156	Generic or branded medicaments in measured retail doses for general clinical treatments.
2	300241	$62.5M	20.45%	42	Preventative human vaccines manufactured for large-scale global public health immunization networks.
3	300390	$21.3M	6.99%	218	Bulk mixed medicaments intended for therapeutic use, not divided into retail doses.
4	300420	$16.4M	5.37%	146	Antibiotic medicaments put up in measured dosage forms for direct consumer use.
5	300439	$7.8M	2.57%	82	Specialized hormone-based medicaments put up in measured retail doses for patient care.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

Mexico's vaccine share at 20.45% is the highest among India's top five destinations, driven by the country's Programa Nacional de Vacunación and the growing role of Indian vaccine manufacturers (Serum Institute of India, Bharat Biotech) in supplying Latin American public health systems.

Key dynamics in India-Mexico pharmaceutical trade:

• Vaccine diplomacy — India's vaccine manufacturing capacity (Serum Institute alone produces 1.5 billion doses annually) positions it as Mexico's primary affordable vaccine source
• The Latin American gateway — Mexico serves as a distribution hub for Indian generics entering Central America and the Caribbean
• Regulatory alignment — COFEPRIS (Mexico's FDA equivalent) has been streamlining approval pathways for Indian generic manufacturers

Top 4 Indian Medicine Export Partner: Kenya — US$261.8 Million

Kenya ranks fourth in India export medicines to which countries at US$261.8 million (3.52%) in Q1/2026. India is Kenya's primary external source of affordable pharmaceuticals, with generic medicaments (HS 300490) leading at 74.94%, followed by hormone-based treatments and antibiotics.

Rank	6-Digit HS Code	Value (US$)	Share %	Shipments	Product Description
1	300490	$196.2M	74.94%	7,496	Generic or branded medicaments in measured retail doses for general clinical treatments.
2	300439	$17.1M	6.52%	344	Specialized hormone-based medicaments put up in measured retail doses for patient care.
3	300420	$13.1M	5.00%	677	Antibiotic medicaments put up in measured dosage forms for direct consumer use.
4	300410	$8.1M	3.09%	244	Medicaments containing penicillins or structural derivatives prepared in therapeutic retail doses.
5	300241	$7.2M	2.76%	49	Preventative human vaccines manufactured for large-scale global public health immunization networks.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

Kenya's dependence on Indian pharmaceuticals is structural — the country's domestic manufacturing covers less than 30% of its total drug consumption, with the remaining 70%+ sourced from imports, predominantly India.

Key dynamics in India-Kenya pharmaceutical trade:

• East African anchor — Kenya serves as the pharmaceutical distribution gateway for the East African Community, with Indian medicines re-distributed to Uganda, Tanzania, Rwanda, and South Sudan
• Public health procurement — KEMSA (Kenya Medical Supplies Authority) and county health systems procure Indian generics at scale for public hospitals and dispensaries
• ARV and antimalarial supply — Indian manufacturers remain critical suppliers of antiretroviral and antimalarial drugs for Kenya's national health programs

Kenya's imports from China surged 16.5% to US$5.18 billion in 2025, with steel, smartphones, and textiles leading the bilateral basket under the new zero-tariff agreement effective May 2026. For broader context on India-Kenya trade dynamics, read the full analysis on yTrade.

Top 5 Indian Medicine Export Partner: Philippines — US$225.6 Million

The Philippines ranks 5th at US$225.6 million (3.03%) in Q1/2026, with a more diversified product mix than most Indian pharmaceutical destinations.

Generic medicaments (HS 300490) lead at 65.54%, but preventative vaccines (HS 300241) at 12.84% and antisera/blood fractions (HS 300212) at 4.04% signal India's growing role in supplying Philippine public health infrastructure.

Rank	6-Digit HS Code	Value (US$)	Share %	Shipments	Product Description
1	300490	$147.8M	65.54%	7,143	Generic or branded medicaments in measured retail doses for general clinical treatments.
2	300241	$29.0M	12.84%	90	Preventative human vaccines manufactured for large-scale global public health immunization networks.
3	300420	$12.3M	5.45%	589	Antibiotic medicaments put up in measured dosage forms for direct consumer use.
4	300212	$9.1M	4.04%	85	Therapeutic antisera and specific blood fractions used for target immune system treatments.
5	300215	$8.5M	3.76%	71	Immunological products packaged in measured retail doses for diagnostic or diagnostic testing.

Data Source: ytrade.com Period: January-March 2026. HS Code Range: 30

The Philippines is India's largest ASEAN pharmaceutical market, driven by growing healthcare demand and government-led procurement of affordable Indian generics.

Key dynamics in India-Philippines pharmaceutical trade:

• Public health procurement — The Philippine government sources Indian generics and vaccines at scale for national immunization and public hospital programs
• Diversified product mix — Unlike the US and Germany's near-exclusive focus on HS 300490, the Philippines imports meaningfully across vaccines (12.84%), antisera (4.04%), and immunological products (3.76%)
• ASEAN growth corridor — Southeast Asian pharmaceutical imports from India are growing as regional healthcare spending expands

Access verified pharmaceutical buyer profiles across the Philippines on yTrade. Importers/exporters/logistics can search verified buyers/suppliers by HS code, purchase frequency, and trade volume, backed by 5+ billion real customs data.

India Medicines Export Market Analysis In 2026

India's pharma exports hit a record US$31 billion in fiscal year 2026 despite facing two major headwinds, reported by India Med Today. yTrade's India trade data highlighted that medicine exports in Q1/2026 reached US$7.4 billion, declining 17.90% from Q4/2025 (US$9.1 billion).

In 2025, peak quarterly exports occurred in Q2/2025 at US$223.9 billion, with the average quarterly change across the year reflecting significant volatility driven by pre-tariff front-loading, demand normalization, and seasonal procurement cycles.

Timeline	Value (US$)	Shipments	QoQ % Change
Q1 2025	$173.6B	822,646	-18.20%
Q2 2025	$223.9B	780,618	29.00%
Q3 2025	$77.5B	593,205	-65.40%
Q4 2025	$9.1B	463,850	-88.30%
Q1 2026	$7.4B	380,608	-17.90%

Data Source: ytrade.com Period: January-December 2025, January-March 2026. HS Code Range: 30

First, Red Sea shipping disruptions raised freight costs 2–3x on key India-to-Africa and India-to-Europe routes, compressing margins for temperature-sensitive medicine shipments.

According to Business Standard, India's March 2026 drug exports contracted for the first time in three years, dragged by the West Asia conflict disrupting shipping routes through the Red Sea and Suez Canal — a factor that affected Q1/2026 Gulf and East African pharmaceutical shipments.

Second, FY25's record US$30.47 billion included accelerated shipments to the US before proposed tariffs took effect.

This front-loading made FY26 comparisons appear softer than actual demand. In fact, exports reached US$28.29 billion through February 2026 alone, confirming that underlying growth remained intact.

Despite these challenges, the outlook is positive. The industry is targeting double-digit export growth by FY27, backed by expanding API manufacturing capacity and rising healthcare budgets across developing economies.

yTrade's exporter solutions for pharmaceutical exporters, importers, and logistics providers:

• Track Indian medicine trade flows across Africa, Latin America, and Asia by HS code and destination
• Monitor competitor export activity and shipment volumes in real time
• Identify new buyer demand before it appears in industry reports
• Screen trade partners for compliance and sanctions risk

Get started now.

Conclusion

India export medicines to which countries?

The market is led by the United States (US$1.3 billion), Germany (US$1.1 billion), and Mexico (US$305.5 million) in Q1/2026 under HS 30. India's pharma exports crossed a record US$31 billion in FY26, with generic medicaments (HS 300490) dominating across all major destinations.

Despite Red Sea shipping disruptions and US tariff-driven demand distortion, underlying growth remained intact, with the industry targeting double-digit expansion by FY27.

Access complete India's complete pharmaceutical export data by HS code, destination, and supplier on yTrade, the most affordable trade data platform for exporters, importers, and sourcing teams.

Frequently Asked Questions

Which countries import medicines from India?

According to yTrade Q1/2026 data, the top importers of Indian medicines (HS 30) are the United States (US$1.3 billion), Germany (US$1.1 billion), Mexico (US$305.5 million), Kenya (US$261.8 million), and the Philippines (US$225.6 million). India ships pharmaceutical products to over 200 countries, with generic medicaments in retail doses (HS 300490) as the dominant product across all markets.

Who can export medicines from India?

Any Indian company registered with the Directorate General of Foreign Trade (DGFT) with a valid Import Export Code (IEC) can export medicines.

Exporters must also register with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and obtain necessary drug licenses from the Central Drugs Standard Control Organisation (CDSCO). Products must meet quality standards of the destination country's regulatory authority — such as the US FDA, EU EMA, or WHO prequalification — depending on the target market.

[]{.lark-record-clipboard}